Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT and will be considered separately as a single arm prospective cohort

Propranolol with Standard Chemoradiation for Esophageal Adenocarcinoma - A Combined Single Arm and Randomized Cohort Phase II Study